Insulet (PODD) EBITDA Margin Growth (3y) (2013 - 2026)
Insulet (PODD) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -343.00 |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 17.00 |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 487.00 |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -283.00 |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 1,505.00 |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -184.00 |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -763.00 |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 829.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 829.00 |
| Dec 31, 2025 | 1,231.00 |
| Sep 30, 2025 | 1,581.00 |
| Jun 30, 2025 | 2,757.00 |
| Mar 31, 2025 | 278.00 |
| Dec 31, 2024 | 214.00 |
| Sep 30, 2024 | 333.00 |
| Jun 30, 2024 | 104.00 |
| Mar 31, 2024 | 642.00 |
| Dec 31, 2023 | 2,386.00 |
| Sep 30, 2023 | 249.00 |
| Jun 30, 2023 | -431.00 |
| Mar 31, 2023 | 395.00 |
| Dec 31, 2022 | -229.00 |
| Sep 30, 2022 | -800.00 |
| Jun 30, 2022 | -1,321.00 |
| Mar 31, 2022 | 826.00 |
| Dec 31, 2021 | 631.00 |
| Sep 30, 2021 | 833.00 |
| Jun 30, 2021 | 664.00 |